Prognostic Significance of Brain-Derived Neurotrophic Factor Levels in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction

Barman, Hasan Ali; Şahin, İrfan; Atıcı, Adem; Durmaz, Eser; Yurtseven, Ece; İkitimur, Barış; Okuyan, Ertuğrul; Keleş, İbrahim

doi:10.14744/anatoljcardiol.2019.37941

Cited by 15 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, obesity, metabolic syndrome, type 2 diabetes mellitus, and CV diseases including HF were associated with decreased serum levels of BDNF [ 122 – 124 ]. In contrast, patients having acute coronary syndrome (ACS) and ST segment elevation myocardial infarction had higher circulating levels of BDNF than healthy volunteers and strongly predicted acute HF development [ 125 ], while there is evidence regarding that BDNF levels can be reduced in patients having ACS [ 126 ]. Moreover, in animal model of HF and among patients with HFrEF, low levels of BDNF were associated with reduced physical activity and a risk of HF-related myopathy [ 127 – 131 ].…”

Section: Myokines In Hf Myopathymentioning

confidence: 99%

“…Moreover, in animal model of HF and among patients with HFrEF, low levels of BDNF were associated with reduced physical activity and a risk of HF-related myopathy [ 127 – 131 ]. In addition, low levels of BDNF predicted a risk of cognitive dysfunction among HFrEF patients [ 132 ] and poor clinical outcomes [ 124 , 125 , 131 , 133 ]. The serum BDNF levels may be a useful surrogate biomarker of increased CV risk, the HF-related myopathy, and adverse prognosis in patients having HF [ 134 ].…”

Section: Myokines In Hf Myopathymentioning

confidence: 99%

“…Myostatin was found to be an independent predictor of mortality in HF patients and rehospitalization due to HF progression [ 107 ]. Decreased serum levels of BDNF were significantly associated with adverse outcomes in HF patients [ 124 , 125 ]. There is a large body of evidence regarding the fact that elevated levels of some SPARC proteins, such as osteonectin and osteopontin, have demonstrated a strong association with poor long-term HF-related outcomes including death, and a risk for recurrent hospitalization due to HF among patients with normal body mass, overweight, and obesity [ 201 , 202 ].…”

Section: Myokines and Heart Failure-related Clinical Outcomesmentioning

confidence: 99%

See 2 more Smart Citations

Myokines and Heart Failure: Challenging Role in Adverse Cardiac Remodeling, Myopathy, and Clinical Outcomes

Berezin

Lichtenauer

2021

Disease Markers

View full text Add to dashboard Cite

Heart failure (HF) is a global medical problem that characterizes poor prognosis and high economic burden for the health system and family of the HF patients. Although modern treatment approaches have significantly decreased a risk of the occurrence of HF among patients having predominant coronary artery disease, hypertension, and myocarditis, the mortality of known HF continues to be unacceptably high. One of the most important symptoms of HF that negatively influences tolerance to physical exercise, well-being, social adaptation, and quality of life is deep fatigue due to HF-related myopathy. Myopathy in HF is associated with weakness of the skeletal muscles, loss of myofibers, and the development of fibrosis due to microvascular inflammation, metabolic disorders, and mitochondrial dysfunction. The pivotal role in the regulation of myocardial and skeletal muscle rejuvenation, attenuation of muscle metabolic homeostasis, and protection against ischemia injury and apoptosis belongs to myokines. Myokines are defined as a wide spectrum of active molecules that are directly synthesized and released by both cardiac and skeletal muscle myocytes and regulate energy homeostasis in autocrine/paracrine manner. In addition, myokines have a large spectrum of pleiotropic capabilities that are involved in the pathogenesis of HF including cardiac remodeling, muscle atrophy, and cardiac cachexia. The aim of the narrative review is to summarize the knowledge with respect to the role of myokines in adverse cardiac remodeling, myopathy, and clinical outcomes among HF patients. Some myokines, such as myostatin, irisin, brain-derived neurotrophic factor, interleukin-15, fibroblast growth factor-21, and growth differential factor-11, being engaged in the regulation of the pathogenesis of HF-related myopathy, can be detected in peripheral blood, and the evaluation of their circulating levels can provide new insights to the course of HF and stratify patients at higher risk of poor outcomes prior to sarcopenic stage.

show abstract

Section: Myokines In Hf Myopathymentioning

confidence: 99%

Section: Myokines In Hf Myopathymentioning

confidence: 99%

Section: Myokines and Heart Failure-related Clinical Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

Myokines and Heart Failure: Challenging Role in Adverse Cardiac Remodeling, Myopathy, and Clinical Outcomes

Berezin

Lichtenauer

2021

Disease Markers

View full text Add to dashboard Cite

show abstract

“…The prognostic significance of BDNF 66ValMet polymorphism was investigated in post-STEMI patients first, while these relations were previously determined in individuals with acute coronary syndrome 35 . Therefore, there was an association between the BDNF levels and severity of HF NYHA functional class among individuals with HF with reduced LVEF (HFrEF) 21 , atherosclerosis severity in stable CAD patients 36 , and patients with unstable angina 37 . The exact causes for the decline in circulating BDNF levels among patients with known CV diseases (including unstable angina, acute coronary syndrome, STEMI and HF) are uncertain.…”

Section: Discussionmentioning

confidence: 99%

“…patients, and CV risk in individuals with known DM, hypertension, cardiomyopathy, stable coronary artery disease and STEMI [18][19][20][21] . However, circulating levels of BDNF exhibited a close correlation with single nucleotide polymorphism (SNP) in BDNF gene that was associated with a replacement of valine to methionine in the 66 position of codon (Val66Met).…”

Section: Introductionmentioning

confidence: 99%

Brain-derived neurotrophic factor gene polymorphism in post-ST-elevation myocardial infarction patients undergoing primary percutaneous intervention

Petyunina¹,

Kopytsya²,

Berezin

2020

Biomed. Res. Ther.

View full text Add to dashboard Cite

Introduction: The goal of this study was to elucidate a link of brain-derived factor (BDNF) Val66Met gene with combined 6-month clinical end points in post-myocardial infarction patients. Methods: 256 post-myocardial infarction patients who underwent primary coronary intervention were enrolled in the study. Variants of Val66Met gene BDNF were identified by real-time chain reaction at baseline. Results: The combined clinical end points (major cardiovascular events and hospitalization) were determined in 61 (23.8%) post-STEMI patients; consequently, 195 (76.2%) patients did not meet the events. linear regression revealed that predictors for combined clinical end points were peak TnI levels, NT-proBNP, SYNTAX score, TIMI score, obesity, left ventricular ejection fraction, and 66ValMet+66MetMet in BDNF gene. The cumulative clinical outcomes (major adverse cardiac events and admission) were determined in 61 (23.8%) patients. Kaplan-Meier curves demonstrated that 66ValVal of BDNF gene was significantly associated with the low number of combined end points. Conclusion: The Val66Met in BDNF gene independently predicted 6-month combined clinical end points in post-myocardial infarction patients.

show abstract

Circulating brain‐derived neurotrophic factor levels and heart failure: A systematic review and meta‐analysis

Behnoush,

Khalaji,

Fazlollahpour‐Naghibi

et al. 2024

ESC Heart Failure

View full text Add to dashboard Cite

AimsBiomarkers are paramount for managing heart failure (HF) patients as prognostic and therapeutic efficacy index tools. Systemic levels of brain‐derived neurotrophic factor (BDNF) can add to the HF biomarker scenario, allowing for potentiated efficacy in diagnosis, prognostic stratification, and prediction of patient response to a given therapeutic intervention because BDNF is one of the primary rulers of myocardial function. Yet, whether BDNF is a reliable clinical biomarker awaits clinical validation. Hence, we aimed to answer this relevant question via a systematic review and meta‐analysis of existing studies.Methods and resultsInternational databases, including PubMed, Scopus, Embase, and the Web of Science, were comprehensively searched for studies assessing BDNF levels in patients with HF versus non‐HF controls or as a prognostic factor for HF complications. Data were extracted and analysed by random‐effect meta‐analysis. Standardized mean difference (SMD) and 95% confidence intervals (CIs) were computed to pool the results of studies. We included 11 studies in the final review, among which six underwent meta‐analysis. These studies analysed 1420 HF patients, with a mean age of 65.4 ± 11.2 years. Meta‐analysis revealed that patients with HF had significantly lower circulating BDNF levels than healthy controls (SMD −2.47, 95% CI −4.39 to −0.54, P‐value = 0.01). Moreover, patients with higher New York Heart Association functional classification had lower levels of BDNF. Adverse clinical outcomes such as all‐cause mortality and HF rehospitalization were also associated with lower levels of BDNF in individual studies.ConclusionsBDNF levels are decreased in patients with HF. Most importantly, we observed an association between lower BDNF levels and poor prognosis in patients with HF. Our study supports BDNF as an easy‐to‐dose diagnostic and prognostic biomarker to be implemented in clinical practice for HF. Further studies are warranted to address this ability specifically.

show abstract

Prognostic Significance of Brain-Derived Neurotrophic Factor Levels in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction

Cited by 15 publications

References 33 publications

Myokines and Heart Failure: Challenging Role in Adverse Cardiac Remodeling, Myopathy, and Clinical Outcomes

Myokines and Heart Failure: Challenging Role in Adverse Cardiac Remodeling, Myopathy, and Clinical Outcomes

Brain-derived neurotrophic factor gene polymorphism in post-ST-elevation myocardial infarction patients undergoing primary percutaneous intervention

Circulating brain‐derived neurotrophic factor levels and heart failure: A systematic review and meta‐analysis

Contact Info

Product

Resources

About